JP2022535130A5 - - Google Patents

Info

Publication number
JP2022535130A5
JP2022535130A5 JP2021572298A JP2021572298A JP2022535130A5 JP 2022535130 A5 JP2022535130 A5 JP 2022535130A5 JP 2021572298 A JP2021572298 A JP 2021572298A JP 2021572298 A JP2021572298 A JP 2021572298A JP 2022535130 A5 JP2022535130 A5 JP 2022535130A5
Authority
JP
Japan
Prior art keywords
fusion protein
polypeptide
amino acid
protein according
mutant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021572298A
Other languages
English (en)
Japanese (ja)
Other versions
JP7778571B2 (ja
JP2022535130A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/036454 external-priority patent/WO2020247843A2/en
Publication of JP2022535130A publication Critical patent/JP2022535130A/ja
Publication of JP2022535130A5 publication Critical patent/JP2022535130A5/ja
Priority to JP2025000023A priority Critical patent/JP2025060983A/ja
Application granted granted Critical
Publication of JP7778571B2 publication Critical patent/JP7778571B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021572298A 2019-06-05 2020-06-05 免疫細胞機能をモジュレートするための変異体インターロイキン-2ポリペプチドと抗原結合分子の融合体 Active JP7778571B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025000023A JP2025060983A (ja) 2019-06-05 2025-01-05 免疫細胞機能をモジュレートするための変異体インターロイキン-2ポリペプチドと抗原結合分子の融合体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962857726P 2019-06-05 2019-06-05
US62/857,726 2019-06-05
PCT/US2020/036454 WO2020247843A2 (en) 2019-06-05 2020-06-05 Fusions of mutant interleukin-2 polypeptides with antigen binding molecules for modulating immune cell function

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025000023A Division JP2025060983A (ja) 2019-06-05 2025-01-05 免疫細胞機能をモジュレートするための変異体インターロイキン-2ポリペプチドと抗原結合分子の融合体

Publications (3)

Publication Number Publication Date
JP2022535130A JP2022535130A (ja) 2022-08-04
JP2022535130A5 true JP2022535130A5 (cg-RX-API-DMAC7.html) 2023-06-13
JP7778571B2 JP7778571B2 (ja) 2025-12-02

Family

ID=73652315

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021572298A Active JP7778571B2 (ja) 2019-06-05 2020-06-05 免疫細胞機能をモジュレートするための変異体インターロイキン-2ポリペプチドと抗原結合分子の融合体
JP2025000023A Pending JP2025060983A (ja) 2019-06-05 2025-01-05 免疫細胞機能をモジュレートするための変異体インターロイキン-2ポリペプチドと抗原結合分子の融合体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025000023A Pending JP2025060983A (ja) 2019-06-05 2025-01-05 免疫細胞機能をモジュレートするための変異体インターロイキン-2ポリペプチドと抗原結合分子の融合体

Country Status (8)

Country Link
US (1) US20220251202A1 (cg-RX-API-DMAC7.html)
EP (1) EP3980051A4 (cg-RX-API-DMAC7.html)
JP (2) JP7778571B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220083660A (cg-RX-API-DMAC7.html)
CN (1) CN114786708A (cg-RX-API-DMAC7.html)
AU (1) AU2020287373B2 (cg-RX-API-DMAC7.html)
CA (1) CA3142738A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020247843A2 (cg-RX-API-DMAC7.html)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110325205B (zh) 2016-12-22 2023-08-15 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
KR20240005989A (ko) 2017-03-15 2024-01-12 큐 바이오파마, 인크. 면역 반응을 조절하는 방법
US20200306301A1 (en) 2017-07-03 2020-10-01 Torque Therapeutics, Inc. Polynucleotides Encoding Immunostimulatory Fusion Molecules and Uses Thereof
WO2019139896A1 (en) 2018-01-09 2019-07-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
WO2020023702A1 (en) 2018-07-25 2020-01-30 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
CA3098930A1 (en) 2018-09-21 2020-03-26 Innovent Biologics (Suzhou) Co., Ltd. Novel interleukin-2 and use thereof
CN114341189A (zh) 2019-06-12 2022-04-12 奥美药业有限公司 全新il-15前药及其应用
WO2020252421A2 (en) * 2019-06-14 2020-12-17 Cugene, Inc. Novel interleukin-2 variants and bifunctional fusion molecules thereof
AU2021205981A1 (en) 2020-01-11 2022-07-14 AskGene Pharma, Inc. Novel masked cytokines and methods of use thereof
IL296209A (en) 2020-05-12 2022-11-01 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of using them
KR20230010251A (ko) 2020-05-13 2023-01-18 보넘 테라퓨틱스, 인크. 단백질 복합체의 조성물 및 그의 사용 방법
EP4175979A2 (en) * 2020-07-02 2023-05-10 Inhibrx, Inc. Polypeptides comprising modified il-2 polypeptides and uses thereof
JP2023541366A (ja) 2020-09-09 2023-10-02 キュー バイオファーマ, インコーポレイテッド 1型真性糖尿病(t1d)を治療するためのmhcクラスii t細胞調節多量体ポリペプチド及びその使用方法
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
KR20230112632A (ko) 2020-10-23 2023-07-27 애셔 바이오테라퓨틱스, 인크. 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합
CN117321087A (zh) 2021-03-26 2023-12-29 先天制药公司 包含与细胞因子融合用于nk细胞衔接的nkp46结合位点、癌抗原结合位点的多特异性蛋白质
MX2023011964A (es) * 2021-04-09 2024-01-08 Ose Immunotherapeutics Nuevo andamio para moléculas bifuncionales con propiedades mejoradas.
WO2022221746A1 (en) * 2021-04-16 2022-10-20 Orionis Biosciences, Inc. Il-2 based constructs
WO2022245500A1 (en) 2021-05-19 2022-11-24 Asher Biotherapeutics, Inc. Il-21 polypeptides and targeted constructs
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
CN117616050A (zh) 2021-06-09 2024-02-27 先天制药公司 与nkp46、细胞因子受体、肿瘤抗原和cd16a结合的多特异性蛋白质
KR20240019786A (ko) 2021-06-09 2024-02-14 이나뜨 파르마 에스.에이. Cd20, nkp46, cd16에 결합하고 il-2에 접합된 다중특이적 항체
TW202317623A (zh) * 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法
TW202309102A (zh) * 2021-07-20 2023-03-01 美商英伊布里克斯公司 靶向cd8之經修飾il-2多肽及其用途
TW202321283A (zh) * 2021-07-20 2023-06-01 美商英伊布里克斯公司 Cd8結合多肽及其用途
EP4376870A4 (en) * 2021-07-28 2025-07-23 Anwita Biosciences Inc INTERLEUKIN-2 MUTEINS, FUSION PROTEINS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC APPLICATIONS
CN118555973A (zh) * 2021-11-17 2024-08-27 豪夫迈·罗氏有限公司 蛋白质复合物的组合物及其使用方法
CN116554344A (zh) * 2022-01-30 2023-08-08 中国科学院生物物理研究所 一种pd1抗体与白介素2融合的双功能分子
CN119546343A (zh) * 2022-04-27 2025-02-28 亚设生物治疗公司 细胞因子融合蛋白与cd8抗原结合分子的组合
IL317511A (en) 2022-06-16 2025-02-01 Cephalon Llc IL-2 immunoconjugates attenuated by anti-PD-1 antibody and their uses
AU2023308064A1 (en) * 2022-07-11 2025-02-27 Genuv Inc. Cytokine fusion protein
CN116162171B (zh) * 2022-10-13 2025-06-03 深圳市百士通科技开发有限公司 抗体突变方法在治疗性抗体药物中的应用
US20260234258A1 (en) * 2022-10-20 2026-08-13 Repertoire Immune Medicines, Inc. Cd8 t cell targeted il2
CN116041539B (zh) * 2022-10-31 2023-07-21 山东博安生物技术股份有限公司 Il-2突变体免疫缀合物
KR20260008731A (ko) * 2023-03-21 2026-01-16 포트비타 바이오로직스 (싱가포르) 피티이. 리미티드 항-pd-1 및 돌연변이 il-2 면역접합체 제제
IL328822A (en) * 2023-12-19 2026-08-01 Cephalon Llc Uses for attenuated IL-2 immunosuppressants
WO2025151752A1 (en) 2024-01-10 2025-07-17 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof
TW202545980A (zh) * 2024-02-01 2025-12-01 瑞典商阿斯特捷利康公司 Cd8結合細胞介素銜接器及其使用方法
CN118373896B (zh) * 2024-04-19 2025-07-29 上海科棋药业科技有限公司 抗pd-1抗体与il-2突变体的双功能融合蛋白
WO2026162740A1 (en) * 2025-01-31 2026-08-06 Astrazeneca Ab Cd8-binding cytokine engager combination therapies

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010085495A1 (en) 2009-01-21 2010-07-29 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
RU2583876C2 (ru) * 2009-08-17 2016-05-10 Роше Гликарт Аг Иммуноконъюгаты направленного действия
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
EP3421495A3 (en) * 2013-03-15 2019-05-15 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
PT3102595T (pt) 2014-02-06 2019-01-11 Hoffmann La Roche Proteínas de fusão de interleucina-2 e suas utilizações
RU2740672C2 (ru) * 2015-08-07 2021-01-19 ЭйЭлЭкс Онколоджи Инк. Конструкции, имеющие sirp-альфа домен или его вариант
CN109071632B (zh) * 2016-02-05 2022-12-30 奥里尼斯生物科学私人有限公司 靶向性治疗剂及其用途
KR20240005989A (ko) 2017-03-15 2024-01-12 큐 바이오파마, 인크. 면역 반응을 조절하는 방법
KR102461885B1 (ko) * 2017-04-03 2022-11-03 에프. 호프만-라 로슈 아게 항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
KR20190136076A (ko) * 2017-04-13 2019-12-09 에프. 호프만-라 로슈 아게 암 치료 방법에 사용하기 위한 인터루킨-2 면역접합체, cd40 작용제 및 임의적인 pd-1 축 결합 길항제
AU2018273914A1 (en) * 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
AU2018287317B2 (en) 2017-06-19 2024-06-20 Medicenna Therapeutics Inc. Uses and methods for IL-2 superagonists, agonists, and fusions thereof
EP3665201A4 (en) 2017-08-09 2021-06-02 Orionis Biosciences, Inc. CD8 BINDERS
KR102777151B1 (ko) 2017-11-21 2025-03-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 인터루킨-2의 부분 효능제
KR20230112632A (ko) * 2020-10-23 2023-07-27 애셔 바이오테라퓨틱스, 인크. 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합

Similar Documents

Publication Publication Date Title
US12448423B2 (en) Targeted heterodimeric Fc fusion proteins containing NKG2D antigen binding domains
JP7857236B2 (ja) 免疫活性化Fcドメイン結合分子
AU2018298881B2 (en) Improved dual specificity polypeptide molecule
JP2025060983A (ja) 免疫細胞機能をモジュレートするための変異体インターロイキン-2ポリペプチドと抗原結合分子の融合体
JP6464255B2 (ja) 二重特異性t細胞活性化抗原結合分子
CN110382539B (zh) 用于cd16a定向的nk细胞结合的串联双抗体
JP5851419B2 (ja) ヘテロダイマー結合タンパク質およびその使用
JP2023548045A5 (cg-RX-API-DMAC7.html)
JP7549961B2 (ja) 少なくともcd3及びhsaを標的とするヘテロ二量体多重特異性抗体フォーマット
KR20200143436A (ko) Nk 세포 결합 항체 융합 구조체
WO2019204646A1 (en) Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains
JP2019533444A (ja) IL−15/IL−15RアルファFc融合タンパク質およびPD−1抗体の断片を含む二重特異性ヘテロ二量体融合タンパク質
RS56879B1 (sr) Bispecifične molekule koje vezuju antigen za aktiviranje t ćelija
RS59992B1 (sr) Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije specifični za cd3 i cea
CA3205670A1 (en) Anti-pd-l1 monoclonal antibodies and fusion proteins with interleukin-15 (il-15), interleukin-15 receptor 15 alpha or interleukin-2
CA3147677A1 (en) Engineered interleukin-2 receptor beta agonists
JP2024508949A (ja) Pd-1標的化il-2変異体イムノコンジュゲートとfap/4-1bb結合分子との併用療法
JP2024512382A (ja) Pd-1標的化il-2バリアント免疫コンジュゲートと抗tyrp1/抗cd3二重特異性抗体の併用療法
US20250339519A1 (en) Combination of cytokine fusion proteins with cd8 antigen binding molecules
KR20260062933A (ko) 항-γδ TCR 항체 및 이의 용도
Muller et al. Diabodies, Single-Chain Diabodies, and Their Derivatives